Hong Li
- Cancer Research top 2%
- Cancer, Hypoxia, and Metabolism 15
- MicroRNA in disease regulation 9
- Molecular Medicine top 2%
- Molecular Biology top 5%
- Epigenetics and DNA Methylation 31
- Cancer-related gene regulation 17
- RNA modifications and cancer 14
- RNA Interference and Gene Delivery 11
- Oncology top 5%
- Cancer Cells and Metastasis 11
- Biomaterials top 5%
-
- Cancer Research and Treatments 8
- Journals
- Proceedings of the National Academy of Sciences (1 paper)Journal of Biological Chemistry (1 paper)Journal of Clinical Investigation (2 papers)
- Partner nations
- ChinaUnited StatesCanada
In The Last Decade
Hong Li
151 papers receiving 4.3k citations
Peers
Comparison fields: 5 of 148
- Cancer Research 1.0k
- Molecular Medicine 179
- Molecular Biology 2.4k
- Oncology 827
- Biomaterials 292
Countries citing papers authored by Hong Li
This map shows the geographic impact of Hong Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hong Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hong Li more than expected).
Fields of papers citing papers by Hong Li
This network shows the impact of papers produced by Hong Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hong Li. The network helps show where Hong Li may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hong Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 2 | |
| 3 | 2025 | 2 | |
| 4 | 2025 | 2 | |
| 5 | 2025 | 1 | |
| 6 | 2024 | 4 | |
| 7 | 2024 | 0 | |
| 8 | 2024 | 0 | |
| 9 | 2023 | 12 | |
| 10 | 2023 | 26 | |
| 11 | 2022 | 5 | |
| 12 | 2022 | 10 | |
| 13 | 2020 | 76 | |
| 14 | 2020 | 39 | |
| 15 | 2019 | 55 | |
| 16 | The transcription factor Ikaros inhibits cell proliferation by downregulating ANXA4 expression in hepatocellular carcinoma. | 2017 | 19 |
| 17 | 2014 | 30 | |
| 18 | 2012 | 82 | |
| 19 | 2002 | 10 | |
| 20 | 1997 | 19 |
About Hong Li
Hong Li is a scholar working on Cancer Research, Oncology and Molecular Biology, having authored 159 papers that have together received 4.4k indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (31 papers), Cancer-related gene regulation (17 papers), Cancer, Hypoxia, and Metabolism (15 papers), RNA modifications and cancer (14 papers), RNA Interference and Gene Delivery (11 papers), Cancer Cells and Metastasis (11 papers), MicroRNA in disease regulation (9 papers) and Cancer Research and Treatments (8 papers). The work is most often cited by research in Cancer Research (1.0k citations), Molecular Medicine (179 citations) and Molecular Biology (2.4k citations). Hong Li has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Chao Ge, Jinjun Li, Fangyu Zhao, Taoyang Chen, Zixing Shi, Min Lian, Jie Yin, Jinchen Fan, Ming Yao and Hua Tian. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.